SIGLEC10

Across TCGA pan-cancer cohorts, SIGLEC10 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SIGLEC10’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SIGLEC10 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIGLEC10 is over-expressed in tumor, although a few such as COAD and PAAD show the opposite, repressed pattern.

KIRC, KIRP, and STAD are the cancer types where SIGLEC10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLEC10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+2.680	<.001	12	view →
KIRP	Male	All	+1.582	<.001	11	view →
STAD	All	II,III,IV	+1.449	<.001	7	view →
HNSC	Female	All	+0.792	.016	6	view →
THCA	All	III,IV	+0.687	.006	6	view →
BRCA	All	All	+0.469	<.001	4	view →
COAD	All	All	−0.444	.012	4	view →
PAAD	All	All	−2.237	.027	2	view →
CHOL	All	All	+1.312	.020	2	view →
KICH	All	All	+0.801	.003	2	view →
LIHC	Male	All	−0.595	.003	2	view →
ESCA	All	All	+1.377	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SIGLEC10–KIRC

Open the KIRC breakdown →